---
title: "Cryoport surges 13% as Q3 revenue tops estimates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304652987.md"
description: "Cryoport rose 12.80% to $18.10 as Q3 revenue beat estimates, adjusted EBITDA turned positive, and FY guidance was raised."
datetime: "2026-11-06T14:31:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304652987.md)
  - [en](https://longbridge.com/en/news/304652987.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304652987.md)
generator: "portal-rs"
---

# Cryoport surges 13% as Q3 revenue tops estimates

Cryoport (CYRX.US) surged nearly **13%** during regular trading to **$18.10**.

The company reported fiscal 2026 third-quarter revenue of **$50.2 million**, up 14% from a year earlier and topping the analyst consensus of $48.8 million. Adjusted EBITDA turned positive at **$1.1 million**, beating estimates of $551,000. Cryoport raised its full-year 2026 revenue guidance to **$197 million to $199 million**, though third-quarter net loss widened 56% year-over-year to **$10.85 million**.

Separately, Cryoport's Paris center received ISO certification, and management highlighted strategic expansion in bioservices capacity.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [CYRX.US](https://longbridge.com/en/quote/CYRX.US.md)

## Related News & Research

- [CryoPort (NASDAQ:CYRX) Stock: Insider Daniel Hancock Sells 74,379 Shares](https://longbridge.com/en/news/305449778.md)
- [Cryoport (CYRX) Lifts 2026 Outlook Following Revenue Update As Fair Value Stays Just Behind](https://longbridge.com/en/news/304925527.md)
- [AI solves 167-year-old maths problem, Anthropic researcher claims](https://longbridge.com/en/news/306318851.md)
- [Marvell Stock’s (MRVL) Plunge Is My Opportunity to Buy](https://longbridge.com/en/news/306273400.md)
- [Keybanc maintains CryoPort at Overweight, raises price target to $20 from $17](https://longbridge.com/en/news/304652048.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**